Stock AnalizRegeneron Pharmaceuticals, Inc. REGN
Biotechnology: Pharmaceutical Preparations · IPO 1991 · data as of November 13, 2026
Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company listed in the US with a market value of about $98.8B. In the twelve months to September 30, 2026 it had revenue of $16.9B and net income of $4.8B, a net margin of 28.5%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is financial health (5/5); the weakest is future growth (2/5).
Key numbers: a P/E of 21.1, a price to free cash flow of 25.8, 5-year revenue growth of 11% a year, a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 17% above the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Checks not passed
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- ROE above 15%
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.9B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $6.6B | $5.1B | $5.9B | $4.9B |
| Net income | $4.8B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M |
| Free cash flow | $3.8B | $4.1B | $3.7B | $3.9B | $4.4B | $6.5B | $2.0B | $2.0B | $1.8B | $1.0B | $974M |
| EPS (diluted) | $45.30 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| Net margin | 28.5% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% |
| ROIC | — | 9.2% | 11.7% | 13.6% | 17.1% | 37.3% | 25.4% | 17.3% | 27.7% | 19.5% | 20.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 27 analysts is $977.93, 2% above the current price; targets range from $812.00 to $1175.00; the consensus rating is “Buy”; expected EPS is $68.75 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Regeneron Pharmaceuticals’s P/E ratio?
About 21.1, based on the last twelve months of diluted earnings per share (forward P/E about 13.2).
Is Regeneron Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 17% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. The dividend yield is about 0.39%, and it has paid dividends for 1 years in our data.
Is Regeneron Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Regeneron Pharmaceuticals scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.